Patrick Terheyden

8.5k total citations · 1 hit paper
107 papers, 3.4k citations indexed

About

Patrick Terheyden is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Patrick Terheyden has authored 107 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 27 papers in Immunology and 26 papers in Molecular Biology. Recurrent topics in Patrick Terheyden's work include CAR-T cell therapy research (30 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Polyomavirus and related diseases (27 papers). Patrick Terheyden is often cited by papers focused on CAR-T cell therapy research (30 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Polyomavirus and related diseases (27 papers). Patrick Terheyden collaborates with scholars based in Germany, United States and United Kingdom. Patrick Terheyden's co-authors include Sandra P. D’Angelo, Célèste Lebbé, Jeffery S. Russell, Howard L. Kaufman, Isaac Brownell, Shailender Bhatia, Kent C. Shih, Michèle Milella, Omid Hamid and Paul Nghiem and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Patrick Terheyden

102 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

2016 933 citations Howard L. Kaufman, Jeffery S. Russell et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Terheyden Germany	23	2.8k	815	813	662	606	107	3.4k
Lisa Mahnke United States	14	1.5k 0.5×	410 0.5×	554 0.7×	440 0.7×	223 0.4×	34	2.0k
Melissa Pulitzer United States	30	1.9k 0.7×	432 0.5×	656 0.8×	632 1.0×	501 0.8×	145	3.2k
Andrew S. Brohl United States	22	1.2k 0.4×	346 0.4×	291 0.4×	230 0.3×	426 0.7×	100	2.0k
Denise Frosina United States	23	2.3k 0.8×	1.9k 2.3×	163 0.2×	150 0.2×	812 1.3×	50	4.2k
Felix Kiecker Germany	19	837 0.3×	324 0.4×	282 0.3×	230 0.3×	405 0.7×	48	1.4k
Guilherme Rabinowits United States	21	1.2k 0.4×	197 0.2×	353 0.4×	290 0.4×	1.4k 2.2×	71	3.1k
Nanette J. Liégeois United States	22	1.7k 0.6×	135 0.2×	251 0.3×	237 0.4×	1.8k 2.9×	33	3.1k
Eric J. Duncavage United States	26	967 0.3×	193 0.2×	214 0.3×	193 0.3×	1.2k 2.0×	76	3.3k
Véronique Winnepenninckx Netherlands	23	985 0.4×	385 0.5×	162 0.2×	136 0.2×	935 1.5×	67	2.0k
Aude G. Chapuis United States	22	1.4k 0.5×	832 1.0×	382 0.5×	288 0.4×	310 0.5×	75	2.1k

Countries citing papers authored by Patrick Terheyden

Since Specialization

Citations

This map shows the geographic impact of Patrick Terheyden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Terheyden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Terheyden more than expected).

Fields of papers citing papers by Patrick Terheyden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Terheyden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Terheyden. The network helps show where Patrick Terheyden may publish in the future.

Co-authorship network of co-authors of Patrick Terheyden

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Terheyden. A scholar is included among the top collaborators of Patrick Terheyden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Terheyden. Patrick Terheyden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lodde, Georg, Ulrike Leiter, Anja Gesierich, et al.. (2025). Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients. European Journal of Cancer. 221. 115406–115406. 1 indexed citations

Gogas, Helen, Andrew J.S. Furness, Gino K. In, et al.. (2025). Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor–naive unresectable or metastatic melanoma: updated results from IOV-COM-202 Cohort 1A. 3. 100624–100624.

Vorobyev, Artem, et al.. (2024). Pemphigoid gestationis is associated with an increased risk for adverse pregnancy outcomes: A large-scale propensity-matched retrospective cohort study. Journal of the American Academy of Dermatology. 91(4). 748–750. 2 indexed citations

Terheyden, Patrick, Cord Sunderkötter, Ralf Baron, et al.. (2023). Varicella Zoster Virus-Specific Hyperimmunoglobulin in the Adjuvant Treatment of Immunocompromised Herpes Zoster Patients: A Case Series. Dermatology and Therapy. 13(10). 2461–2471. 3 indexed citations

Becker, Jürgen C., Ambros J. Beer, Thomas Eigentler, et al.. (2023). S2k‐Leitlinie – Merkelzellkarzinom – Update 2022. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 21(3). 305–317. 2 indexed citations

Pruessmann, Jasper N., Ewan A. Langan, Jan Rupp, et al.. (2022). Challenge of hepatitis B testing following intravenous immunoglobulin therapy in patients with autoimmune skin diseases. The Journal of Dermatology. 49(10). 1049–1051. 4 indexed citations

Stege, Henner, Maximilian Haist, Peter Mohr, et al.. (2021). Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study. Cancer Immunology Immunotherapy. 70(11). 3313–3322. 17 indexed citations

Sadik, Christian D., Ewan A. Langan, Ralf Gutzmer, et al.. (2021). Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers. Frontiers in Immunology. 11. 588582–588582. 28 indexed citations

Busch, Hauke, et al.. (2021). The impact of the Covid-19 pandemic on quality of life in skin cancer patients. PLoS ONE. 16(8). e0255501–e0255501. 12 indexed citations

10.

Spassova, Ivelina, Selma Ugurel, Patrick Terheyden, et al.. (2020). Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. Clinical Cancer Research. 26(9). 2257–2267. 52 indexed citations

11.

Haferkamp, Sebastian, Mareike Alter, Dirk Debus, et al.. (2020). Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of Choice. Advances in Therapy. 37(8). 3619–3629. 5 indexed citations

12.

Langan, Ewan A., et al.. (2019). Kutanes Angiosarkom. Der Hautarzt. 70(9). 700–706. 3 indexed citations

13.

Zillikens, Detlef, et al.. (2019). Sequential Treatment With Targeted and Immune Checkpoint Therapy in Patients With BRAF Positive Metastatic Melanoma: The Importance of Timing?. Frontiers in Medicine. 6. 257–257. 1 indexed citations

14.

D’Angelo, Sandra P., Jeffery S. Russell, J.C. Hassel, et al.. (2017). Avelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC). Annals of Oncology. 28. v435–v436. 2 indexed citations

15.

Langan, Ewan A., et al.. (2017). Meningeal melanomatosis following discontinuation of dabrafenib: implications for the maintenance of long-term complete remission. Melanoma Research. 27(5). 503–506. 2 indexed citations

16.

Garbe, Claus, Patrick Terheyden, Ulrich Keilholz, Oliver Kölbl, & Axel Hauschild. (2008). Treatment of Melanoma. Deutsches Ärzteblatt international. 105(49). 845–51. 16 indexed citations

17.

Schrama, David, Patrick Terheyden, Ulrike Kämmerer, et al.. (2005). Expression of the NKG2D ligand UL16 binding protein‐1 (ULBP‐1) on dendritic cells. European Journal of Immunology. 36(1). 65–72. 22 indexed citations

18.

Terheyden, Patrick, et al.. (2004). Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. Journal of Cancer Research and Clinical Oncology. 130(7). 395–9. 13 indexed citations

19.

Terheyden, Patrick & Eva‐Bettina Bröcker. (2003). Hautveränderungen bei Schilddrüsenerkrankungen. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 1(4). 306–317. 1 indexed citations

20.

Terheyden, Patrick, Per thor Straten, Eva‐B. Bröcker, Eckhart Kämpgen, & Jürgen C. Becker. (2000). CD40-Ligated Dendritic Cells Effectively Expand Melanoma-Specific CD8+ CTLs and CD4+ IFN-γ-Producing T Cells from Tumor-Infiltrating Lymphocytes. The Journal of Immunology. 164(12). 6633–6639. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact